Movement Disorders

Filter Your Results




Positive Two-Year Outcomes for Treatment of Essential Tremor With Focused Ultrasound

Tuesday, October 09, 2018—Patients with medically refractory essential tremor treated with magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy had a mean 43.4% reduction in their scores o…

Shortage of Sinemet Attribute to Manufacturing and Forecasting Issues

Thursday, October 04, 2018—The carbidopa-levodopa distributed under the brand names Sinemet and Sinemet Plus by Merck &Co. (Kenilworth, NJ) is out of stock and expected to be on back order through t…

Smart Phone Tests May Distinguish Parkinson’s from Idiopathic REM Sleep Behavior Disorder

Tuesday, September 25, 2018—In a paper published in Neurology, researchers report that consumer-grade smartphones can be used to accurately identify patients with Parkinson’s disease (PD) versus th…

FDA Analysis Finds No New or Unexpected Safety Risks of Pimavanserin:Benefits Outweigh Risks

Thursday, September 20, 2018—The Food and Drug Administration (FDA) announced that there are no new safety concerns for pimavanserin (Nuplazid; Acadia Pharma, San Diego, CA). Pimavanserin is approved for …

Assessing Relative Neuropsychologic Performance in Patients with Parkinson’s Requires Comparison to Site-Specific Health Controls

Friday, September 14, 2018—In a study published online in the journal Movement Disorders (September 14, 2018), meta-analysis was used to examine the use of neuropsychologic testing to detect early cogni…

Criteria for Clinically-Established Early Parkinson’s Disease Published

Tuesday, August 28, 2018—Using the 2015 clinical diagnostic criteria for Parkinson’s disease (PD), a team of researchers have developed criteria specifically for early Parkinson’s disease,…

Safety and Efficacy of Opicapone for Patients With Parkinson’s Disease

Tuesday, August 21, 2018—Safety and efficacy results for opicapone (Neurocrine Biosciences, San Diego, CA), an investigational treatment for end-of-dose motor symptoms, termed off-time, in patien…

Long-Term Safety and Efficacy of Valbenazine for Patients With Tardive Dyskinesia

Monday, August 20, 2018—Long-term results for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), a treatment for patients with tardive dyskinesia (TD), are being presented at the 2018 Wor…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.